Evidence map›Paper›PMID 41046343›Full record

ArticleJournal of diabetes science and technology2025

Use of the Glycemia Risk Index at Hybrid Closed-Loop Initiation to Predict Combined International Glucose Targets at 12 Months: Results From the CIRDIA Study Group.

Sylvie Picard, Joëlle Dupont, Fabienne Amiot-Chapoutot, Blandine Courbebaisse, Estelle Personeni, Emmanuelle Lecornet-Sokol, François Mougel, Clara Bouché, Françoise Giroud, Sandrine Lablanche and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of diabetes science and technology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Sylvie PicardEndocrinology and Diabetes, Point Medical, Dijon, France.ORCID 0000-0003-0463-8063
Joëlle DupontEndocrinology and Diabetes, HPL, Saint-Etienne, France.
Fabienne Amiot-ChapoutotEndocrinology and Diabetes, Senons Health Center, Sens, France.
Blandine CourbebaisseEndocrinology and Diabetes Office, Fontenay-sous-Bois, France.
Estelle PersoneniEndocrinology and Diabetes Office, Châtenoy-le-Royal, France.
Emmanuelle Lecornet-SokolEndocrinology and Diabetes, IPE, Paris, France.
François MougelEndocrinology and Diabetes, Mutualite 39 health center, Lons-le-Saunier, France.
Clara BouchéEndocrinology and Diabetes, Rothschild Foundation, Paris, France.
Françoise GiroudCDOM21, CROM, Dijon, France.ORCID 0009-0002-8522-8727
Sandrine LablancheEndocrinology and Diabetes, University Hospital Grenoble Alpes, Grenoble, France.ORCID 0000-0001-7044-8474
Sophie BorotEndocrinology and Diabetes, University Hospital, Besançon, France.ORCID 0000-0001-6240-8253

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHybrid closed-loop (HCL) therapy helps reaching efficacy and safety glucose targets (ESGT+) in persons with type 1 diabetes (PwT1D). We analyzed here the glycemia risk index (GRI) in PwT1D at HCL initiation (M

methodsThis was a retrospective study. Consecutive PwT1D who started HCL in a CIRDIA center were included after written consent. Glucose parameters were manually extracted from platforms at M

resultsM

conclusionsM

Indexed as

glucose targetsglycemia risk index (GRI)hybrid closed looptype 1 diabetes

Identifiers

PMID41046343
PMCPMC12867718

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.